Analytical Data
-
基因名
SLC25A20
- Application
-
别名
SLC25A20；CAC；CACT；；Mitochondrial carnitine/acylcarnitine carrier Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O43772
-
表达区间
1-301aa
-
氨基酸序列
MADQPKPISPLKNLLAGGFGGVCLVFVGHPLDTVKVRLQTQPPSLPGQPPMYSGTFDCFRKTLFREGITGLYRGMAAPIIGVTPMFAVCFFGFGLGKKLQQKHPEDVLSYPQLFAAGMLSGVFTTGIMTPGERIKCLLQIQASSGESKYTGTLDCAKKLYQEFGIRGIYKGTVLTLMRDVPASGMYFMTYEWLKNIFTPEGKRVSELSAPRILVAGGIAGIFNWAVAIPPDVLKSRFQTAPPGKYPNGFRDVLRELIRDEGVTSLYKGFNAVMIRAFPANAACFLGFEVAMKFLNWATPNL
-
分子量
59.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC25A20, also known as the mitochondrial carrier protein, plays a critical role in cellular metabolism by facilitating the transport of acylcarnitines across the mitochondrial membrane. Its dysfunction has been implicated in various metabolic disorders, particularly in the context of mitochondrial fatty acid oxidation. The study of SLC25A20 recombinant protein is crucial for understanding its structural and functional properties, which may shed light on the mechanisms underlying related pathologies. Research indicates that mutations in the SLC25A20 gene can lead to severe clinical manifestations, including neonatal-onset metabolic crises, cardiomyopathy, and neurological deficits. Moreover, insights into the protein’s transport mechanisms can contribute to the development of therapeutic strategies targeting mitochondrial dysfunctions. By producing recombinant SLC25A20 in an experimental setting, scientists aim to elucidate its transport kinetics, substrate specificity, and the effects of various inhibitors. This research is fundamental for comprehensively understanding the physiological role of SLC25A20 and its potential as a target for pharmacological interventions in metabolic diseases.
